Compass Therapeutics (NASDAQ:CMPX) Reaches New 12-Month High on Analyst Upgrade

Compass Therapeutics, Inc. (NASDAQ:CMPX)’s share price reached a new 52-week high on Monday after Jefferies Financial Group raised their price target on the stock from $7.00 to $8.00. Jefferies Financial Group currently has a buy rating on the stock. Compass Therapeutics traded as high as $3.95 and last traded at $3.94, with a volume of 359782 shares changing hands. The stock had previously closed at $3.50.

Other equities research analysts have also issued reports about the company. D. Boral Capital restated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.17.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. SG Americas Securities LLC boosted its position in shares of Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after buying an additional 356,352 shares during the last quarter. Barclays PLC grew its stake in shares of Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after acquiring an additional 112,614 shares during the period. Catalina Capital Group LLC purchased a new position in shares of Compass Therapeutics during the fourth quarter valued at approximately $71,000. The Manufacturers Life Insurance Company bought a new position in Compass Therapeutics during the third quarter valued at approximately $79,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Compass Therapeutics in the 2nd quarter worth approximately $41,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Trading Down 6.4 %

The firm has a market capitalization of $502.20 million, a PE ratio of -9.86 and a beta of 1.17. The business’s 50 day simple moving average is $2.16 and its two-hundred day simple moving average is $1.76.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. As a group, equities research analysts anticipate that Compass Therapeutics, Inc. will post -0.35 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.